Clinical trials: Rivaroxaban
Anticoagulation
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
- Trial name
- NCT02640222
- Testing
- VKA, Apixaban, dabigatran
- Where
- France
- Volunteers
- 321,501 people
- Sponsor
- Bristol-Myers Squibb
Non-Valvular Atrial Fibrillation
Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
By evaluating routine clinical practice data from the UK primary care database, researchers in this study want to gather information on the kidney function of patients with non-valvular atrial fibrillation (NVAF, irregularly…
- Trial name
- ANTENNA (NCT04297072)
- Testing
- Rivaroxaban (Xarelto, BAY-597939), VKAs
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- Bayer
Pulmonary Embolism, Thromboembolism
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of…
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis
- Trial name
- EinsteinChoice (NCT02064439)
- Testing
- BAY 59-7939, ASA
- Where
- 266 sites in United States, Australia and 29 more
- Volunteers
- 3,365 people
- Sponsor
- Bayer
Direct Oral Anticoagulant, Hemmorhage
Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly
This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.
- Conditions
- Direct Oral Anticoagulant, Hemmorhage, Elderly, Muscle Mass
- Trial name
- SARCORRHAGED (NCT07173075)
- Testing
- impedancemetry
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Clermont-Ferrand
Peripheral Artery Disease
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure.
- Trial name
- PADELTO (NCT04824729)
- Testing
- Lower limb revascularization
- Where
- France
- Volunteers
- 227,613 people
- Sponsor
- Bayer
Peripheral Arterial Disease
Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
Assessing the outcomes of using Rivaroxaban plus Aspirin in patients with Lower Extremity Peripheral Arterial Disease after Endovascular Revascularization
- Trial name
- NCT05308030
- Testing
- Rivaroxaban and Aspirin
- Volunteers
- 100 people
- Sponsor
- Assiut University
Atrial Fibrillation, Stroke
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who…
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- PACES (NCT04045665)
- Testing
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Where
- 106 sites in United States, Brazil and 3 more
- Volunteers
- 3,200 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
- Trial name
- XANTUS (NCT01606995)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 6,784 people
- Sponsor
- Bayer
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Pelvic Pain
Treatment of Pelvic Ring Fractures in the Elderly
Pelvic ring fractures in the elderly are associated with high morbidity during standard conservative treatment due to immobility. Furthermore the risk of long term dependence even after the fracture has united is high.
- Trial name
- NCT02590783
- Testing
- experimental intervention surgery, control intervention
- Where
- Switzerland
- Volunteers
- 88 people
- Sponsor
- University Hospital, Basel, Switzerland
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03596502
- Testing
- Direct oral anticoagulants (DOACs), Warfarin
- Where
- Canada
- Volunteers
- 402,764 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Effect of NOAC on POCT
Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices
Concentration determinations of anticoagulants require plasma instead of whole blood, and results are not immediately available to clinicians.
- Trial name
- NCT01613443
- Volunteers
- 100 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Atherosclerosis of Artery, Coronary Artery Disease
Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
Primary Study Objective : To compare the effects of low-dose rivaroxaban plus aspirin versus aspirin on atherosclerotic plaque inflammation using serial FDG Positron Emission Tomography/Computed Tomography(PET-CT) imaging of…
- Conditions
- Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease, Carotid Stenosis
- Trial name
- SPIRIT (NCT05797376)
- Testing
- Rivaroxaban 2.5mg
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Asan Medical Center
Aging
Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults
The goal of this observational study aims to reveal the pharmacokinetics of clinical probes and characteristics of endogenous biomarkers for drug-metabolizing enzymes and transporters in Chinese older adults and old older adults…
- Trial name
- NCT05893849
- Testing
- Clinical probes
- Where
- China
- Volunteers
- 624 people
- Sponsor
- Peking University Third Hospital
Non-valvular Atrial Fibrillation (NVAF)
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied.
- Trial name
- RENOVATOR (NCT05022758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- South Korea
- Volunteers
- 45,000 people
- Sponsor
- Bayer
Atrial Fibrillation
Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic)…
- Trial name
- NACO-VP (NCT02814955)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen
Non-valvular Atrial Fibrillation
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation
In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to…
- Trial name
- NCT03002740
- Sponsor
- Bristol-Myers Squibb
Heparin-induced Thrombocytopenia
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
Heparin is an anticoagulant (blood thinner) that is commonly used to treat patients with heart attacks and patients with blood clots in their legs or lungs (venous thrombosis).
- Trial name
- NCT01598168
- Testing
- Rivaroxaban
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McMaster University